Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Irbesartan

A sartan for hypertension that blocks the AT1 receptor of angiotensin II: patented in 1990 and approved in 1997, it is also used to slow kidney damage in hypertensive patients with type 2 diabetes. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards, nitrosamines and other impurities.

Did you know?Unlike several other sartans it is not a prodrug: it is already active as it is, with no need to be converted by the body, and 60-80% of an oral dose is absorbed.

IrbesartanGo to the active ingredient →
IrbesartanActive ingredientIrbesartanCat. No. P-I075-001CAS 138402-11-6
Irbesartan-d4Isotopically labelledIrbesartan-d4Cat. No. P-I075-012CAS 1216883-23-6
Irbesartan-D7Isotopically labelledIrbesartan-D7Cat. No. P-I075-013CAS 1329496-43-6

EDQM standards 2

The official European Pharmacopoeia standards for this family.

Reference substanceIrbesartan CRSEDQM code Y0001166Family Irbesartan

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.